Please wait while the formulary information is being retrieved.
LEMTRADA (ALEMTUZUMAB)
- Relapsing form of multiple sclerosis
- Secondary progressive multiple sclerosis
12 mg/1.2 mL intravenous solution
- Infuse 1.2 milliliters (12 mg) over 4 hour(s) by intravenous route once daily for 5 consecutive days
Relapsing form of multiple sclerosis
- Infuse 1.2 milliliters (12 mg) over 4 hour(s) by intravenous route once daily for 5 days
- Infuse 1.2 milliliters (12 mg) over 4 hour(s) by intravenous route once daily for 3 days
- Infuse 1.2 milliliters (12 mg) over 4 hour(s) by intravenous route once daily for 5 consecutive days
- Infuse 1.2 milliliters (12 mg) over 4 hour(s) by intravenous route once daily for 3 consecutive days
Secondary progressive multiple sclerosis
- Infuse 1.2 milliliters (12 mg) over 4 hour(s) by intravenous route once daily for 5 days
- Infuse 1.2 milliliters (12 mg) over 4 hour(s) by intravenous route once daily for 3 days
- Infuse 1.2 milliliters (12 mg) over 4 hour(s) by intravenous route once daily for 5 consecutive days
- Infuse 1.2 milliliters (12 mg) over 4 hour(s) by intravenous route once daily for 3 consecutive days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Acute thromboembolic stroke
- Cervicocephalic arterial dissection
- Hemorrhagic stroke
- HIV infection
- Lactating mother
- Progressive multifocal leukoencephalopathy
Contraindicated
- Active tuberculosis
- Aplastic anemia
- Bacterial infection
- Glomerulonephritis
- Hemolytic anemia
- Herpes simplex infection
- Herpes zoster
- Inactive tuberculosis
- Listeriosis
- Malignancy
- Neutropenic disorder
- Pancytopenia
- Pregnancy
- Protozoal infection
- Thrombocytopenic disorder
Severe
Moderate
- Chronic hepatitis B
- Chronic hepatitis C
- Hyperthyroidism
- Hypothyroidism
- Interstitial pneumonitis
- Lymphopenia
LEMTRADA (ALEMTUZUMAB)
- Relapsing form of multiple sclerosis
- Secondary progressive multiple sclerosis
- Anemia
- Cardiac arrhythmia
- Chills
- Cytokine release syndrome
- Dyspnea
- Fever
- Headache disorder
- Lymphopenia
- Neutropenic disorder
- Pruritus of skin
- Skin rash
- Tachycardia
- Thrombocytopenic disorder
- Urticaria
- Wheezing
- Arthralgias
- Bronchitis
- Dizziness
- Fatigue
- Nausea
- Pain in oropharynx
- Paresthesia
- Pharyngitis
- Sinusitis
- Urinary tract infection
More Frequent
Severe
Less Severe
- Bacterial infection
- Bacterial sepsis
- Fungal infection
- Herpes zoster
- Hypersensitivity drug reaction
- Hypertension
- Hyperthyroidism
- Hypotension
- Hypothyroidism
- Infection
- Influenza
- Pneumonia
- Viral infection
- Acute abdominal pain
- Anorexia
- Diarrhea
- Dysesthesia
- Erythema
- Herpes simplex infection
- Insomnia
- Oral candidiasis
- Stomatitis
- Vomiting
- Vulvovaginal candidiasis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute cholecystitis without calculus
- Acute myocardial infarction
- Acute respiratory distress syndrome
- Acute respiratory insufficiency
- Alveolar hemorrhage
- Anaphylaxis
- Angina
- Angioedema
- Aplastic anemia
- Arterial dissection
- Aspergillosis
- Atrial fibrillation
- Autoimmune hemolytic anemia
- Autoimmune hepatitis
- Bone marrow hypoplasia
- Cardiac arrest
- Cardiomyopathy
- Cerebrovascular accident
- Cervicocephalic arterial dissection
- Chemotherapy-induced hyperuricemia
- Chronic heart failure
- Chronic inflammatory demyelinating polyneuropathy
- Coccidioidomycosis
- Cytomegalovirus disease
- Eosinophilia
- Glomerulonephritis
- Goiter
- Goodpasture's syndrome
- Graves' disease
- Guillain-barre syndrome
- Hashimoto thyroiditis
- Hemophagocytic lymphohistiocytosis
- Hemorrhagic stroke
- Histoplasmosis
- Hyperbilirubinemia
- Hypersensitivity pneumonitis
- Idiopathic thrombocytopenic purpura
- Infectious mononucleosis
- Interstitial pneumonitis
- Kidney disease with reduction in GFR
- Listeriosis
- Malignant lymphoma
- Malignant melanoma
- Nocardiosis
- Opportunistic viral infection
- Optic neuropathy
- Pancytopenia
- Pneumocystis jirovecii pneumonia
- Progressive multifocal leukoencephalopathy
- Pulmonary hemorrhage
- Pulmonary infiltrates
- Serum sickness
- Sinus bradycardia
- Suicidal
- Suicidal ideation
- Thyroid carcinoma
- Thyroiditis
Less Severe
- Cholecystitis
- Conjunctivitis
- Dry eye
- Ocular pain
- Periorbital edema
- Photophobia
- Purpura
- Symptoms of anxiety
- Tinnitus
- Tremor
- Visual changes
Contraindicated
None
Severe Precaution
Alemtuzumab
Risk of autoimmune conditions, stroke, and malignancy (thyroid, melanoma, lymphoproliferative disorders, and lymphoma). Possible life threatening infusion reaction. Not recommended for age < 17 years.
- 1 Day – 17 Years
- Risk of autoimmune conditions, stroke, and malignancy (thyroid, melanoma, lymphoproliferative disorders, and lymphoma). Possible life threatening infusion reaction. Not recommended for age < 17 years.
Management or Monitoring Precaution
None
Alemtuzumab
- Severity Level:
D
- Additional Notes: Insuff human data avail. tx can result in autoantibodies that may cross placenta
Contraindicated
Alemtuzumab
Insuff human data; potential for serious adverse effects; caution advised
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insuff human data; potential for serious adverse effects; caution advised |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication may cause very serious (rarely fatal) blood disorders (decreased bone marrow function leading to low number of blood cells such as red cells, white cells, and platelets). This effect can cause anemia, decrease your body's ability to fight an infection, or cause your body to bruise or bleed more easily. Tell your doctor right away if you develop any of the following symptoms: signs of infection (such as fever, persistent sore throat), easy bruising/bleeding, coughing up blood, unusual tiredness, fast/pounding heartbeat, dark urine.<br /><br /> This medication may also cause very serious (rarely fatal) infusion-related reactions. (See also Side Effects section.) This medication may increase your risk of developing certain types of cancer (such as thyroid, skin). Tell your doctor right away if you notice symptoms such as unusual growth or lump in the neck, difficulty swallowing, shortness of breath, unusual/lasting hoarseness.<br /><br /> This medication may also cause very serious kidney problems. Tell your doctor right away if you notice symptoms such as change in the amount of urine, painful urination, pink/bloody urine, or swelling ankles/feet. This medication may also cause stroke or tears in the blood vessels in the head and neck, especially within the first 3 days after receiving treatment.<br /><br />Get medical help right away if you notice symptoms such as weakness on one side of the body, drooping of the face, neck pain, sudden severe headache, trouble speaking, sudden vision changes, or confusion. Your doctor will monitor you closely to decrease the risk of these serious side effects. To receive this medication, all doctors, pharmacists, and patients must understand, agree to, and carefully follow the requirements of the Lemtrada REMS Program.<br /><br />These requirements apply in the United States. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.
| Relapsing form of multiple sclerosis | |
| G35 | Multiple sclerosis |
| Secondary progressive multiple sclerosis | |
| G35 | Multiple sclerosis |
| 0-9 | A-Z |
|---|---|
| G35 | Multiple sclerosis |
| G35 | Multiple sclerosis |
Formulary Reference Tool